Techbio x Africa: Early Movers - part3
5145
Early Signs, Real Ventures
It's one thing to say the infrastructure and talent are here but the real test is whether it yields actual companies.
And the signs are already showing. A new class of TechBios is taking shape, raising money, and doing the first thing every good TechBio does:
… drum roll, you should know it by now…
Building proprietary datasets.
The support system is forming too. OneBio, a Cape Town venture studio, closed a $47M Series A to back founders at the biology–technology edge.
Villgro Africa in Nairobi has already incubated 40+ health and life science startups and unlocked $18M in follow-on capital. These are strides stimulate the Techbio ecosystem and in part, to close Africa's translation gap with venture tools.
And the startups coming out of this wave are telling. I thought I would share my personal pick here. Start-ups I can map on the playbook trajectory.
Yemaachi Biotech in Ghana raised $3M from YC, Tencent, and LoftyInc to build the world's most diverse cancer knowledge base, sequencing samples across the continent to power precision oncology. As founder Yaw Bediako put it:
"We're looking at trying to understand cancer in the African diaspora - African American, Black British, and continental Africans - the first initiative of its scale. You can't say you're studying a disease if you don't include the most diverse population on the planet, which is the Black population."
BioCertica in South Africa, backed by Pronexus and the Gates Foundation's I3 program with a $2.2M seed, runs consumer genetic tests but is really playing the long game of building the first African polygenic risk database.
And Bixbio, part of OneBio's portfolio and an Illumina Accelerator graduate, assembled the largest reference dataset ever from Southern Africa, nearly 400 high-quality genomes across eight ethno-linguistic groups.
Even newcomers like Pandora Biosciences are starting on the same path, building chronic disease datasets designed for drug discovery.
And just this summer, the signal got even stronger. In June 2025, Revna Biosciences, a Ghanaian precision medicine startup, announced a landmark partnership with AstraZeneca. Within months, EGFR (gene coding for cell growth protein) biomarker testing integrated into Ghanaian cancer centers, oncologists trained in precision protocols, and the rollout of one of AstraZeneca's targeted therapies for lung cancer patients.
For a sub-Saharan market that has historically had near-zero access to this kind of precision oncology, that's nothing short of historic.
As Revna's CEO Dr. Derrick Edem Akpalu put it:
"This collaboration exemplifies how a synergized biomedical ecosystem such as RevnaBio's can help address long-standing institutional voids that have limited access to advanced molecular diagnostics and targeted therapies in this region."
It's a textbook case of a TechBio going from data and diagnostics to being a direct bridge for global Pharma into Africa.
None of this is random. Data-first plays are the starting point of TechBio always.
In the West, consumer genomics followed the same arc: 23andMe built a database of 15M genomes, went bankrupt, and still got snapped up in 2025 by Regeneron for $256M because Pharma wanted the dataset.
Tempus, sitting on 20 petabytes of oncology data, signed a $160M licensing deal with Recursion to train AI models for biomarker discovery and patient stratification.
The lesson is obvious: even before a molecule is in sight, the data itself is valuable enough to Pharma. Africa's first TechBios are now running that playbook and they're doing it from the most diverse human dataset on the planet.
The Stakes for Africa x TechBio
Case Study: 54gene - The Right Start, The Wrong Turn
54gene was supposed to be Africa’s genomics moonshot. Founded in 2019 by Dr. Abasi Ene-Obong, the company set out to fix the glaring gap where less than 3% of global genomic data came from Africans despite the continent holding the greatest genetic diversity on earth. Backed by Y Combinator, Adjuvant Capital, and Cathay AfricInvest, it raised $45M across three rounds and quickly became the poster child for African TechBio.
The model at first was exactly what you’d expect from a good TechBio: start with the data. 54gene partnered with 10 of Nigeria’s largest hospitals, built a biobank that grew past 100,000 patient samples, and focused on high-value cohorts like cancer, cardiovascular disease, diabetes, and sickle cell.
This was the right first play: position as an enabler for hospitals and research centers, pile up proprietary datasets, and generate revenue through paid Pharma collaborations. In other words, service-led first, platform-led later — the same arc followed by U.S. genomics pioneers like 23andMe.
Then came COVID. 54gene pivoted into diagnostics, scaling mobile labs and at one point driving Nigeria’s daily testing capacity from 100 to over 1,000. Revenues spiked — over $20M from COVID testing — but the pivot also pulled the company away from its core playbook. Instead of doubling down on turning its biobank into translational insights with AI, it spun up Seven Rivers Labs, a costly diagnostics arm. The bets didn’t pay off.
By 2022, as COVID demand collapsed, 54gene was caught between a fading diagnostics business and a stalled genomics mission. Layoffs, valuation cuts, and boardroom fights followed. In 2023 the company shut down operations; by 2025, its assets, including the biobank of 100,000 Nigerian genomes were up for sale at just $3M, before a Lagos court froze the deal amid lawsuits between founder and investors.
The story matters because it shows how fragile the trajectory can be.
Imagine if instead of diagnostics, 54gene had invested its datasets into AI models to map dosage differences for African populations, identify new drug targets, or partner on stratified clinical trials. That’s the road from platform to assets, the road that makes a TechBio a unicorn.
Dr. Ene-Obong seems to agree. His new company, Syndicate Bio, is now doubling down on the same thesis but with AI built in from day one partnering on cancer genomics in Nigeria and aiming to turn Africa’s diversity into global drug discovery.
It’s the continuation of the playbook 54gene set in motion, but with the missing piece restored.
Share:
Techbio x Africa: Early Movers - part3
copy:
https://bluwr.com/p/413338542